Aqeel Hashmi, MD
Psychiatry · Houston, TXNPI 1083900955
Payments from drug & device makers
Across 449 payments — averaging $2932.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$593K
- Boehringer Ingelheim$357K
- Janssen Research & Development, LLC$102K
- AbbVie$60K
- Boehringer Ingelheim International GmbH$47K
- Teva Pharmaceuticals USA, Inc.$38K
- plus $120K from 16 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 16 | $592,596 |
| Boehringer Ingelheim | 31 | $356,964 |
| Janssen Research & Development, LLC | 11 | $102,149 |
| AbbVie(2 entities) | 40 | $59,734 |
| Boehringer Ingelheim International GmbH | 76 | $46,759 |
| Teva Pharmaceuticals USA, Inc. | 103 | $37,934 |
| Hoffmann-la Roche Limited | 8 | $30,621 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $28,100 |
| H. Lundbeck A S | 8 | $19,525 |
| Acadia Pharmaceuticals Inc | 2 | $13,200 |
| Alkermes, Inc. | 35 | $13,080 |
| Neurocrine Biosciences, Inc. | 36 | $8,896 |
| Boehringer Ingelheim RCV GmbH & Co KG | 2 | $5,125 |
| Johnson & Johnson | 32 | $883 |
| Otsuka America Pharmaceutical, Inc. | 22 | $445 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $126 |
| Indivior Inc. | 6 | $106 |
| Axsome Therapeutics, Inc. | 4 | $77 |
| Lundbeck LLC | 2 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| Luye Pharma (USA) Ltd. | 1 | $16 |
How this compares
$1,316,488 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Asim ShahHouston$2.2M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Rayan Al JurdiHouston$712K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.